Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation

Shinji Takeuchi, Koji Fukuda, Tadaaki Yamada, Sachiko Arai, Satoshi Takagi, Genichiro Ishii, Atsushi Ochiai, Shotaro Iwakiri, Kazumi Itoi, Hisanori Uehara, Hiroshi Nishihara, Naoya Fujita, Seiji Yano

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is characterized by dissemination and aggressive growth in the thoracic cavity. Podoplanin (PDPN) is an established diagnostic marker for MPM, but the function of PDPN in MPM is not fully understood. The purpose of this study was to determine the pathogenetic function of PDPN in MPM. Forty-seven of 52 tumors (90%) from Japanese patients with MPM and 3/6 (50%) MPM cell lines tested positive for PDPN. Knocking down PDPN in PDPN-high expressing MPM cells resulted in decreased cell motility. In contrast, overexpression of PDPN in PDPN-low expressing MPM cells enhanced cell motility. PDPN stimulated motility was mediated by activation of the RhoA/ROCK pathway. Moreover, knocking down PDPN with short hairpin (sh) RNA in PDPN-high expressing MPM cells resulted in decreased development of a thoracic tumor in mice with severe combined immune deficiency (SCID). In sharp contrast, transfection of PDPN in PDPN-low expressing MPM cells resulted in an increase in the number of Ki-67-positive proliferating tumor cells and it promoted progression of a thoracic tumor in SCID mice. Interestingly, PDPN promoted focus formation in vitro, and a low level of E-cadherin expression and YAP1 activation was observed in PDPN-high MPM tumors. These findings indicate that PDPN is a diagnostic marker as well as a pathogenetic regulator that promotes MPM progression by increasing cell motility and inducing focus formation. Therefore, PDPN might be a pathogenetic determinant of MPM dissemination and aggressive growth and may thus be an ideal therapeutic target.

Original languageEnglish
Pages (from-to)696-703
Number of pages8
JournalCancer Science
Volume108
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1
Externally publishedYes

Fingerprint

Cell Movement
Severe Combined Immunodeficiency
Neoplasms
Malignant Mesothelioma
Thorax
Thoracic Cavity
Cadherins
Growth
Small Interfering RNA
Transfection
Cell Line
Therapeutics

Keywords

  • focus formation
  • mesothelioma
  • motility
  • podoplanin
  • YAP1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Takeuchi, S., Fukuda, K., Yamada, T., Arai, S., Takagi, S., Ishii, G., ... Yano, S. (2017). Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. Cancer Science, 108(4), 696-703. https://doi.org/10.1111/cas.13190

Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. / Takeuchi, Shinji; Fukuda, Koji; Yamada, Tadaaki; Arai, Sachiko; Takagi, Satoshi; Ishii, Genichiro; Ochiai, Atsushi; Iwakiri, Shotaro; Itoi, Kazumi; Uehara, Hisanori; Nishihara, Hiroshi; Fujita, Naoya; Yano, Seiji.

In: Cancer Science, Vol. 108, No. 4, 01.04.2017, p. 696-703.

Research output: Contribution to journalArticle

Takeuchi, S, Fukuda, K, Yamada, T, Arai, S, Takagi, S, Ishii, G, Ochiai, A, Iwakiri, S, Itoi, K, Uehara, H, Nishihara, H, Fujita, N & Yano, S 2017, 'Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation', Cancer Science, vol. 108, no. 4, pp. 696-703. https://doi.org/10.1111/cas.13190
Takeuchi, Shinji ; Fukuda, Koji ; Yamada, Tadaaki ; Arai, Sachiko ; Takagi, Satoshi ; Ishii, Genichiro ; Ochiai, Atsushi ; Iwakiri, Shotaro ; Itoi, Kazumi ; Uehara, Hisanori ; Nishihara, Hiroshi ; Fujita, Naoya ; Yano, Seiji. / Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. In: Cancer Science. 2017 ; Vol. 108, No. 4. pp. 696-703.
@article{908684d1e59d4a4b8cab84b9cea59336,
title = "Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation",
abstract = "Malignant pleural mesothelioma (MPM) is characterized by dissemination and aggressive growth in the thoracic cavity. Podoplanin (PDPN) is an established diagnostic marker for MPM, but the function of PDPN in MPM is not fully understood. The purpose of this study was to determine the pathogenetic function of PDPN in MPM. Forty-seven of 52 tumors (90{\%}) from Japanese patients with MPM and 3/6 (50{\%}) MPM cell lines tested positive for PDPN. Knocking down PDPN in PDPN-high expressing MPM cells resulted in decreased cell motility. In contrast, overexpression of PDPN in PDPN-low expressing MPM cells enhanced cell motility. PDPN stimulated motility was mediated by activation of the RhoA/ROCK pathway. Moreover, knocking down PDPN with short hairpin (sh) RNA in PDPN-high expressing MPM cells resulted in decreased development of a thoracic tumor in mice with severe combined immune deficiency (SCID). In sharp contrast, transfection of PDPN in PDPN-low expressing MPM cells resulted in an increase in the number of Ki-67-positive proliferating tumor cells and it promoted progression of a thoracic tumor in SCID mice. Interestingly, PDPN promoted focus formation in vitro, and a low level of E-cadherin expression and YAP1 activation was observed in PDPN-high MPM tumors. These findings indicate that PDPN is a diagnostic marker as well as a pathogenetic regulator that promotes MPM progression by increasing cell motility and inducing focus formation. Therefore, PDPN might be a pathogenetic determinant of MPM dissemination and aggressive growth and may thus be an ideal therapeutic target.",
keywords = "focus formation, mesothelioma, motility, podoplanin, YAP1",
author = "Shinji Takeuchi and Koji Fukuda and Tadaaki Yamada and Sachiko Arai and Satoshi Takagi and Genichiro Ishii and Atsushi Ochiai and Shotaro Iwakiri and Kazumi Itoi and Hisanori Uehara and Hiroshi Nishihara and Naoya Fujita and Seiji Yano",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/cas.13190",
language = "English",
volume = "108",
pages = "696--703",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation

AU - Takeuchi, Shinji

AU - Fukuda, Koji

AU - Yamada, Tadaaki

AU - Arai, Sachiko

AU - Takagi, Satoshi

AU - Ishii, Genichiro

AU - Ochiai, Atsushi

AU - Iwakiri, Shotaro

AU - Itoi, Kazumi

AU - Uehara, Hisanori

AU - Nishihara, Hiroshi

AU - Fujita, Naoya

AU - Yano, Seiji

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Malignant pleural mesothelioma (MPM) is characterized by dissemination and aggressive growth in the thoracic cavity. Podoplanin (PDPN) is an established diagnostic marker for MPM, but the function of PDPN in MPM is not fully understood. The purpose of this study was to determine the pathogenetic function of PDPN in MPM. Forty-seven of 52 tumors (90%) from Japanese patients with MPM and 3/6 (50%) MPM cell lines tested positive for PDPN. Knocking down PDPN in PDPN-high expressing MPM cells resulted in decreased cell motility. In contrast, overexpression of PDPN in PDPN-low expressing MPM cells enhanced cell motility. PDPN stimulated motility was mediated by activation of the RhoA/ROCK pathway. Moreover, knocking down PDPN with short hairpin (sh) RNA in PDPN-high expressing MPM cells resulted in decreased development of a thoracic tumor in mice with severe combined immune deficiency (SCID). In sharp contrast, transfection of PDPN in PDPN-low expressing MPM cells resulted in an increase in the number of Ki-67-positive proliferating tumor cells and it promoted progression of a thoracic tumor in SCID mice. Interestingly, PDPN promoted focus formation in vitro, and a low level of E-cadherin expression and YAP1 activation was observed in PDPN-high MPM tumors. These findings indicate that PDPN is a diagnostic marker as well as a pathogenetic regulator that promotes MPM progression by increasing cell motility and inducing focus formation. Therefore, PDPN might be a pathogenetic determinant of MPM dissemination and aggressive growth and may thus be an ideal therapeutic target.

AB - Malignant pleural mesothelioma (MPM) is characterized by dissemination and aggressive growth in the thoracic cavity. Podoplanin (PDPN) is an established diagnostic marker for MPM, but the function of PDPN in MPM is not fully understood. The purpose of this study was to determine the pathogenetic function of PDPN in MPM. Forty-seven of 52 tumors (90%) from Japanese patients with MPM and 3/6 (50%) MPM cell lines tested positive for PDPN. Knocking down PDPN in PDPN-high expressing MPM cells resulted in decreased cell motility. In contrast, overexpression of PDPN in PDPN-low expressing MPM cells enhanced cell motility. PDPN stimulated motility was mediated by activation of the RhoA/ROCK pathway. Moreover, knocking down PDPN with short hairpin (sh) RNA in PDPN-high expressing MPM cells resulted in decreased development of a thoracic tumor in mice with severe combined immune deficiency (SCID). In sharp contrast, transfection of PDPN in PDPN-low expressing MPM cells resulted in an increase in the number of Ki-67-positive proliferating tumor cells and it promoted progression of a thoracic tumor in SCID mice. Interestingly, PDPN promoted focus formation in vitro, and a low level of E-cadherin expression and YAP1 activation was observed in PDPN-high MPM tumors. These findings indicate that PDPN is a diagnostic marker as well as a pathogenetic regulator that promotes MPM progression by increasing cell motility and inducing focus formation. Therefore, PDPN might be a pathogenetic determinant of MPM dissemination and aggressive growth and may thus be an ideal therapeutic target.

KW - focus formation

KW - mesothelioma

KW - motility

KW - podoplanin

KW - YAP1

UR - http://www.scopus.com/inward/record.url?scp=85017577559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017577559&partnerID=8YFLogxK

U2 - 10.1111/cas.13190

DO - 10.1111/cas.13190

M3 - Article

C2 - 28182302

AN - SCOPUS:85017577559

VL - 108

SP - 696

EP - 703

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 4

ER -